Adlai Nortye (NASDAQ:ANL) Shares Gap Up to $12.40

Adlai Nortye Ltd. (NASDAQ:ANL) shares gapped up prior to trading on Monday . The stock had previously closed at $12.40, but opened at $13.75. Adlai Nortye shares last traded at $13.75, with a volume of 27,872 shares.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Adlai Nortye in a report on Friday, January 12th.

Adlai Nortye Stock Up 12.6 %

The firm’s fifty day moving average price is $8.83 and its 200-day moving average price is $9.21.

Institutional Trading of Adlai Nortye

A hedge fund recently raised its stake in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its position in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 40,310 shares of the company’s stock after purchasing an additional 22,644 shares during the quarter. Cantor Fitzgerald L. P. owned approximately 0.11% of Adlai Nortye worth $362,000 as of its most recent filing with the Securities & Exchange Commission. 35.21% of the stock is owned by institutional investors.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.